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Background: Between 2010–2013, South Africa implemented WHO ‘Option A’ for prevention of mother to child
transmission (PMTCT), where all HIV-infected pregnant women (from 14 weeks gestation) received zidovudine (AZT)
as ARV prophylaxis and initiated CD4 testing at their first antenatal care (ANC) visit. After returning for a second visit
to collect CD4 results, women with CD4 counts ≤ 350 were referred to the ART clinic and fast-tracked for initiation
on lifelong ART while continuing to visit the ANC clinic every four weeks. Women with CD4 counts >350 were
dispensed daily AZT prophylaxis at monthly follow up visits (every 4 weeks). The primary objective of this study was
to evaluate adherence of HIV-infected pregnant women to recommended PMTCT services at and after their first
antenatal care (ANC) visit.
Methods: We conducted an observational cohort study from August 2012 to February 2013 at two primary health
care clinics in Johannesburg, South Africa using routinely collected clinic data from first ANC visit for up to 60 days.
Results: Of the 158 patients newly diagnosed with HIV at their first ANC visit, records indicated that 139 women
initiated CD4 testing during their first ANC visit. 52 patients (33% of 158) did not return again to the clinic within
60 days. Of the 118 (84% of 139) women with known gestational age > 13 weeks and known Hb ≥ 8 g/dl who
should have received a 4-week supply of daily AZT at first ANC visit, 81 women (69% of 118) had a record of AZT
being dispensed. Among the 139 women with CD4 results, 72 (52%) were eligible for lifelong ART (CD4 count
≤350); however, only 2 initiated ART within 30 days.
Conclusions: Loss to initiation of both single and triple ARV therapy, loss to follow-up, and treatment interruptions
were common during ANC care for pregnant women with HIV after their first ANC visit.
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Between 2010–2013, South Africa implemented the
World Health Organization’s (WHO) ‘Option A’ for pre-
vention of mother to child transmission (PMTCT),
where all HIV-infected pregnant women (from 14 weeks
gestation) received zidovudine (AZT) as ARV prophy-
laxis and initiated CD4 testing at their first antenatal* Correspondence: kschnipp@gmail.com
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unless otherwise stated.care (ANC) visit. Under this policy, after returning for a
second visit to collect CD4 results, women with CD4
counts ≤ 350 were referred to the antiretroviral (ART)
clinic and fast-tracked for initiation on lifelong ART
while continuing to visit the ANC clinic every four
weeks. Women with CD4 counts >350 were dispensed
daily AZT prophylaxis at monthly follow up visits (every
4 weeks). HIV-negative women were scheduled to visit
the ANC clinic every six weeks for a basic package of
services including retesting for HIV at 32 weeks gesta-
tion. Very little information exists to document imple-
mentation of this policy along key steps in the PMTCTral. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/4.0), which permits unrestricted use, distribution, and
iginal work is properly credited. The Creative Commons Public Domain
g/publicdomain/zero/1.0/) applies to the data made available in this article,
Schnippel et al. BMC Infectious Diseases  (2015) 15:46 Page 2 of 6cascade. In April 2013, South Africa adopted Option B,
where triple therapy through cessation of breastfeeding
replaced daily AZT for women not eligible for life-long
ART; at the end of 2014, South Africa adopted Option B+,
where all HIV-infected pregnant women are eligible for
life-long ART regardless of CD4 count. Each new PMTCT
policy has expanded access to ART for a larger proportion
of pregnant women. However, overall the steps of the
PMTCTcascade are the same.
A 2012 evaluation of the PMTCT program in South
Africa found that HIV testing during pregnancy was
nearly universal (98% uptake) and that the rate of
mother-to-child HIV transmission, as measured by
6 week infant testing, had declined to 3.5% [1]. To elim-
inate mother-to-child transmission in South Africa, im-
plementation of PMTCT services, and adherence along
the PMTCT cascade, will be needed. To date, informa-
tion on these topics remains lacking. Thus, to provide
additional information on early adherence to guidelines
by patients and providers for ARV treatment or prophy-
laxis, laboratory testing, initiation, and drug refills, we
conducted a prospective and retrospective, observational
cohort study of pregnant women newly diagnosed with
HIV presenting at two primary health care clinics in
Johannesburg, South Africa.
Methods
This combined prospective and retrospective, observa-
tional cohort study was conducted at two Johannesburg
public-sector primary health centers based in a semi-
urban informal settlement from September 2012 to
February 2013. Both sites provided HIV counseling and
testing, ANC, PMTCT and ART services as well as other
outpatient services to the general population. Women
are referred to a 24-hour community health center or
hospital nearby for labor and deliveries. Data for this
analysis were extracted from routinely collected informa-
tion included in standardized clinic registers for preg-
nant women (18 years or older) newly diagnosed with
HIV from their first ANC visit for up to 60 days of
follow-up. Patients requesting to be transferred to an-
other (non-study) site for further ANC or HIV care were
excluded as information about follow-up visits would
not be available in the clinic. Patients diagnosed with
TB, with known HIV status at first ANC visit, or un-
known HIV status at the conclusion of the first visit
were excluded from the study as their schedule of clinic
visits was different from the standard for newly HIV-
infected ANC.
Standard practice at both clinics was for all new ANC
patients to attend the clinic on a designated ANC day(s)
each week to receive group pre-test counseling for HIV
testing from a lay counselor and to have provider-
initiated rapid HIV testing. For pregnant women testingHIV-positive, intended practice at the sites was to initi-
ate CD4 testing by having blood drawn and sent to the
laboratory and to receive a 4-week supply of AZT
prophylaxis (if at least 14 weeks gestation) from the
ANC nurse. AZT is counter-indicated for severely
anemic women (hemoglobin (Hb) < 8 g/dl) per the South
African PMTCT guidelines [2] and thus point of care
Hb testing was available at both clinics. No information
was available about maternal viral load. Viral load testing
is not routinely done in South Africa prior to initiation
on ART; guidelines indicate testing after 6 months on
treatment.
HIV-infected women were counseled to return in a
week to obtain their CD4 test results, at which point
they would be referred to the ART section of the clinic
on the same premises to be fast-tracked (i.e. within two
weeks) for ART initiation if eligible (CD4 ≤ 350). The
policy of fast-tracking pregnant women for ART initi-
ation allowed for clinics to start treatment without three
sessions for adherence counseling (the standard of care).
At the one-week visit to learn CD4 test results, all HIV-
infected women were also reminded to return to the
clinic in 3 weeks for the next ANC visit and a next 4-
week refill of their AZT (if not on ART). Both clinics
had also designated one day each week for follow-up
ANC visits, for both HIV-infected and uninfected
women.
For this analysis, we evaluated adherence to recom-
mended guidelines (intended standard practice) [2]
based on 5 primary outcomes representing specific types
of visits or steps along the PMCTC cascade within the
60-day follow up period for the study:
1. The proportion presenting for their first ANC visit
within 20 weeks gestation;
2. The proportion initiating CD4 testing (i.e. have
blood drawn and sent to laboratory) at the first
ANC visit;
3. The proportion initiating AZT prophylaxis at their
first ANC visit (for all women at least 14 weeks
gestation and with Hb ≥ 8 g/dl);
4. The proportion receiving their CD4 test results
within 3 weeks (1 week is intended practice);
5. The proportion of known ART-eligible patients
initiating ART within 1 month and 2 months from
their first ANC visit (within 2 weeks of CD4 test
results is intended practice); OR returned to the site
for AZT refill within 4 weeks of first AZT dispensed
for those not eligible for ART.
The study team extracted patient-level data from
ANC, laboratory, and clinic registers as well as ART pa-
tient files or electronic medical records at the clinics and
entered the data into a Census and Survey Processing
Figure 1 Patient enrolment and exclusions.
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time of the study, no individual patient records (medical
files) were kept at the clinic for ANC patients. Data were
analyzed using STATA (Version 12, College Station,
TX). We estimated simple proportions of women meet-
ing the defined criteria for outcomes 1–5 outlined
above.
Ethics
Approval for this study protocol was received from the
Institutional Research Board of Boston University
Medical Center and from the Human Research Ethics
Committee of the University of the Witwatersrand. All
prospectively enrolled patients (September 2012 to
February 2013) provided informed consent. A waiver of
informed consent was granted to retrospectively review
clinic records for patients who presented at the clinic in
the month of August 2012. All study participants were
at least 18 years of age.
Results
During the study period, 308 HIV-infected women had
their first ANC visit at one of the two clinics. Of these,
54 women received ANC services outside of the desig-
nated ANC services days and were therefore not seen by
study staff. In addition, 66 pregnant women knew their
HIV status prior to the ANC visit during the study
period, of whom 25 were already on ART at their first
ANC visit. Other exclusions were 3 women who trans-
ferred to another ANC site and 5 women who were
<18 years of age. 19 HIV-infected women were excluded
because of a clinic stock out of HIV rapid test kits;
nurses and patients had to wait for laboratory HIV test
results to return before treatment could be initiated. Al-
though TB symptom screening was documented in the
registers and some women were tested for TB, no
women were excluded for TB co-infection. The consort
diagram for the study is presented as Figure 1.
Of the 161 HIV-infected pregnant women eligible for
the study, 3 declined consent, and 107 and 51 were en-
rolled at each clinic, for a total of 158. Women pre-
sented at a median age of 26 years (IQR: 24 – 30) and
during their 2nd pregnancy. Patient characteristics are
presented in Table 1.
Table 2 presents results for each primary outcome,
stratified by ART eligibility. We summarize the key re-
sults for each primary outcome below.
Outcome 1. Presented for first ANC prior to 20 weeks
gestation
Gestational age could not be determined for eight women,
meaning that last menstrual period, gestational age, and
expected due date were all missing from clinic records.
The median gestational age was 24 weeks (IQR: 19–28) attheir first ANC visit; 39 (26% of 150) of women attended
ANC prior to 20 weeks gestation, and only nine women
(6% of 150) presented at first ANC prior to 14 weeks
gestation.
Outcome 2. Initiated CD4 testing at first ANC visit
19 women did not have records of initiating CD4 testing
at their first ANC visit. For 139 who initiated CD4 test-
ing at their first visit, and thus have a CD4 test result,
the median CD4 count was 340 (IQR: 197–468). 72
(46%) were eligible for lifelong ART (triple therapy) ac-
cording to guidelines in place at the time (CD4 count
≤350) at their first ANC visit. Clinical staging was poorly
documented; 86 (54%) of women had a WHO clinical
HIV stage recorded. Of these, only 1 woman was re-
corded as stage 3 and therefore eligible for ART regard-
less of CD4.
Outcome 3. Initiated AZT prophylaxis at first ANC visit for
eligible women
No Hb result was recorded for 18 women (11%). Of
the women with pregnancies at least 14 weeks gesta-
tion (n = 141) at their first ANC visit, 7 had an Hb level
that was less than 8 g/dl. Of the 118 (84%) women with
known gestational age at least 14 weeks and known
Hb ≥ 8 g/dl who should have received a 4-week supply
of daily AZT at their first ANC visit, 81 women (69%)
had a record of AZT being dispensed at their first
ANC.
Outcome 4. Received CD4 count results within 3 weeks of
first ANC visit
52 patients (33% of 158) did not return to the clinic
within 60 days of their first ANC visit. For the 67% of
women who did return at least once within 60 days of
their first ANC visit, 30% returned within 3 weeks of the
Table 1 Patient characteristics, stratified by ART eligibility
All women CD4 ≤ 350 CD4 > 350
Enrolled in study 158 72 67
Maternal age, years 26 (IQR: 24–30) 27 (IQR: 25–31) 23 (IQR: 25–29)
Gravidity 2 (IQR: 2–3) 2 (IQR: 2–3) 2 (IQR: 2–3)
Parity 1 (IQR: 1–2) 1 (IQR: 1–2) 1 (IQR: 1–2)
Median gestational age at first ANC, weeks 24 (IQR: 19–28) 24 (IQR: 20–29) 23 (IQR: 18–27)
Median CD4 count 340 (IQR: 197–468) 211.5 (IQR: 134–262.5) 472 (IQR: 410–651)
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ing the 60-day follow up period, the median number of
days from their first to second visit was 28 (IQR: 8 – 34).
Outcome 5a. For those known to be eligible for ART,
initiated ART within 30 days of their first ANC visit
ART records indicated that 2 out of 72 women known
to be eligible for lifelong ART (3%) initiated ART within
30 days of their first ANC visit (i.e. fast-tracking
worked), and a total of 15 of 72 women (21%) initiated
ART within 60 days. The median number of days fromTable 2 Adherence to PMTCT guidelines, stratified by ART eli
1. First ANC visit prior to 20 weeks gestation
No record of gestational age, last menstrual period, or expected date of deliv
<20 weeks gestation at first ANC
2. Initiate CD4 testing at first ANC visit
CD4 tests results from first ANC found
WHO clinical stage found
3. Initiate AZT prophylaxis when first eligible (at least 14 weeks gestation and Hb
>13 weeks gestation at first visit
Hb≥ 8 g/dl at first visit
Known eligible for AZT
Received AZT at first visit, if eligible
4. Receive CD4 count results
Have CD4 results visit recorded
Made a return visit to clinic <3 weeks
Made a return visit to within 60 days
Median days to CD4 results received (n = 106)
5. Initiate ART within 30 days of first ANC or receive 60-day uninterrupted supply
Initiate ART within 30 days of first ANC
Initiated ART within 60 days of first ANC
Median days to ART initiation (n = 15)
Weeks gestation at ART initiation (n = 15)
Receive 60-day uninterrupted supply of AZT
Received 60-day supply of AZT within 60 days
Median days from first AZT to 2nd AZT (n = 20)
/1 N/A = not applicable.first ANC visit until ART initiation was 47, meaning that
women were starting ART only at the beginning of their
third trimester for those who initiated treatment at the
site.
Outcome 5b. For those not eligible for ART, received an
uninterrupted supply of AZT during the 60-day follow up
According to ANC registers, only 10 out of 67 women
with CD4 > 350 (15%) received an uninterrupted 60-day
supply of AZT; i.e. only 15% of women returned on time
for their AZT refill after 4 weeks. Among those notgibility
All women CD4 ≤ 350 CD4 > 350
158 72 67
ery 8 (5%) 4 (6%) 4 (6%)
39 (26%) 15 (21%) 20 (30%)
139 (88%) 72 67
86 (54%) 43 (60%) 32 (48%)
≥ 8 g/dl)
141 (89%) 65 (90%) 58 (87%)
132 (84%) 56 (78%) 60 (90%)
118 (75%) 51 (72%) 52 (78%)
81 (69%) 37 (73%) 32 (62%)
53 (38%) 36 (50%) 17 (25%)
38 (24%) 24 (33%) 13 (19%)
96 (69%) 47 (65%) 49 (73%)
28 (IQR: 8–34) 19 (IQR: 8–29) 29 (IQR: 8–36)
of AZT
N/A/1 2 (3%) N/A
N/A 15 (21%) N/A
N/A 47 (IQR: 37–57) N/A
N/A 27 (IQR: 24–33) N/A
N/A N/A 10 (15%)
N/A N/A 20 (30%)
N/A N/A 31 (IQR: 29–36)
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the 60-day follow up period.
Discussion
In this combined prospective and retrospective observa-
tional cohort study, clinic records for HIV-infected preg-
nant women indicated multiple delays and interruptions
as well as loss to follow-up in the initiation and continu-
ation of AZT and lifelong ART. Maternal age, gravidity,
parity, and baseline CD4 count of ART-eligible women
diagnosed with HIV at first ANC were similar to previ-
ously reported studies in South Africa; median gestational
age was slightly younger [3-5]. In this study, ART-eligible
women presented at a median gestation age of 24 weeks.
The proportion of ART-eligible women who initiated
treatment within 60 days was surprisingly low (21%).
While women who did not initiate ART within the 60 days
follow-up may still have initiated ART prior to delivery,
duration on ART, and therefore the potential effectiveness
of ART [6,7], would have been limited. The long delays in
initiation, treatment interruptions, and high loss to treat-
ment found in this study occurred despite large-scale im-
plementation of interventions in PMTCT programs in
South Africa, including fast-tracking of pregnant women
with reduced adherence counseling and ART preparation,
nurse-initiation of ART, and integration of ANC and ART
services at the same clinic.
Initiation of AZT was also below expectation. Accord-
ing to clinic files, only 69% of women who were docu-
mented as being eligible for initiation of AZT received
AZT at their first visit. 11% of women were missing Hb
test results, which has clinical implications for the man-
agement of anemia as well as AZT eligibility. Problems
which limited the same day initiation of AZT in this
study are likely to carry over to the new Option B+
guidelines implemented in South Africa, which call for
all HIV-infected women to receive a fixed-dose, triple
therapy combination at first ANC visit.
The current study was not designed to determine the
cause of the problems with initiation and adherence.
Clinic managers and nursing staff at the sites indicated
that AZT, when available, was always dispensed. How-
ever, multiple health systems issues that have been iden-
tified elsewhere as barriers to adherence to PMTCT
regimens [8] were encountered during the study period.
One clinic experienced a stock-out of HIV rapid test kits
and enrollment was interrupted as women had to return
to the clinic for laboratory-generated HIV results before
initiating CD4 test and receiving AZT. The other clinic
experienced repeated stock-outs of AZT, including one
period of more than 6 weeks (just prior to the study
period) when AZT was not available. Health care worker
shortages caused difficulties for patient care as well, es-
pecially during holiday periods as staff members on leavefor studying, vacation, or illness were not replaced.
Thus, women may have presented for care but been
turned away because of staff, drugs, or consumable
shortages.
The two clinics were selected for convenience reasons
and may not be generalizable to other clinics within
South Africa. However, both clinics are located within
the city of Johannesburg and thus, on average, are more
likely to have access to staffing, consumables, and super-
vision than facilities in more rural and remote areas.
The study was designed to evaluate the early steps of
the PMTCT cascade, and in particular whether interven-
tions such as same day initiation of AZT for all women
and fast tracking of ART initiation for eligible women
were occurring; therefore, a short period of follow-up
was chosen. This study also did not match mother-
infant pairs to determine if the delays, losses and inter-
ruptions documented here affected transmission; it may
be that treatment is robust despite these challenges.
While women may have initiated ART, continued AZT
beyond the 60 days, or delivered a healthy, HIV-free
baby, earlier initiation maximizes the opportunity for
prevention [6,7].
A limitation of this study is that it was a review of
clinic records; it may be that clinical practice differed
from what was recorded in clinic records. However, for
HIV-infected persons initiating ART, patient medical in-
formation is written in individual patient files, kept by
the facility and stored within the ART clinic; one of the
clinics also captured patient files into an electronic med-
ical record system for HIV management. For this set of
pregnant women, who are both ANC and ART patients,
their medical records from first presentation at the ART
clinic within the sites are as good as for any other ART
patients (and only 21% known eligible initiated treat-
ment with 60 days of HIV testing).
However, within the ANC clinic itself, no individual
clinic-maintained patient files or clinic cards were in use
at the time of the study. ANC patient cards are to be
completed at each visit and women are strongly encour-
aged to bring these patient cards to each visit and at de-
livery. Nursing staff are asked to duplicate, by hand,
information recorded in the patient cards in the clinic
ANC register as well. It may be that some of the missing
visits identified in this analysis were completed by the
patients and recorded in the patient cards but never re-
corded in the ANC clinic register.
Each ANC clinic had one ANC register, which is a
very large format hardcover, pre-printed book with
follow-up visits marked at 6-weekly intervals. Because
each clinic had one large register, it was kept in a central
location. With more than one nurse providing antenatal
care, so that the single ANC register could not always be
in front of the nurse for initial or follow-up visits, nurses
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clinic’s ANC register during the consultation. Nurses
solved this constraint by writing patient-visit information
onto separate sheets of paper during a patient inter-
action, with the intent of later transcribing such infor-
mation back into the ANC register. This may have been
a reason for poor capturing into the register of Hb, ges-
tational age, and WHO staging. During the study period,
however, study staff remained at the sites to complete
this transcribing for the sites so that information ex-
tracted from the ANC register during the study period
was as complete as information obtained at the sites.
Study staff also used a pregnancy due date wheel tool
from the clinic to fill in missing information for last
menstrual period, weeks gestation at time of clinic visit,
or expected delivery date. Beyond the study period, such
after-the-fact transcribing into the large-format ANC
register was no longer completed by study staff and re-
mains a barrier to information management at the sites.
Printed registers and patient cards with follow-up
visits marked at 6-weekly intervals for ANC care of
HIV-negative women may also have contributed to poor
adherence by both the facilities and the patients to the
increased number of visits required for ANC care if
HIV-infected. Patients were told during their first visit
to return in a week for CD4 results, dispensed a 4-week
supply of AZT, and received an ANC patient card indi-
cating 6-week visit. For those who returned for a second
for a second visit, the median time from first visit to
CD4 results was 28 days, coinciding with a need to re-
turn to the clinic for a 4-week AZT refill.
Additional registers (e.g. recording return visits for
CD4 results, referral to ART initiation, and counseling
for ART initiation) were in use throughout the two
clinics, mostly informal hand-drawn columns in note-
books. These registers were organized according to the
particular use of that section of the clinic (e.g. date of
first visit, date of current visit, patient name, patient date
of birth, or ANC register number), which caused diffi-
culties in tracing patients through the services. Neither
clinic site had dedicated staff for assisting in record
keeping or data management for these patients; there-
fore, study staff assisted the clinics in collecting informa-
tion from the different sources and completing registers
during the period. Again, beyond the study period, the
time required for this after-the-fact tracing of patients
across the multiple registers is a barrier to information
and patient management at the sites.
Conclusions
This review of clinic records on initiation of AZT
prophylaxis and ART for newly-identified HIV-infected
women presenting for ANC care in Johannesburg found
multiple delays and gaps in scheduled visits, delays ininitiation of appropriate treatment, and gaps in treat-
ment once initiated. Consolidation of registers and adap-
tation of clinic records to current guidelines, so that it is
possible for clinics to capture information completely
and accurately, in a manner that is feasible for clinic staff
to complete, remains an important first step to identify-
ing the cause of the delays, interruptions and loss to care
documented in this study.
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